Bridgefront Capital, LLC Immunovant, Inc. Transaction History

Bridgefront Capital, LLC

  • $249 Million
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 12, 2022
SELL
$3.38 - $5.65 $11,333 - $18,944
-3,353 Reduced 17.65%
15,649 $61,000
Q1 2022

May 13, 2022
BUY
$5.06 - $8.77 $96,150 - $166,647
19,002 New
19,002 $105,000
Q3 2021

Nov 12, 2021
SELL
$7.01 - $11.37 $95,420 - $154,768
-13,612 Closed
0 $0
Q2 2021

Aug 12, 2021
BUY
$9.4 - $16.85 $127,952 - $229,362
13,612 New
13,612 $144,000

Others Institutions Holding IMVT

# of Institutions
211
Shares Held
66.9M
Call Options Held
2.3M
Put Options Held
631K
View Full List

About Immunovant, Inc.

IMVT Quotes by TradingView
  • Ticker IMVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 129,077,000
  • Market Cap $3.55B
  • Description
  • Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...
More about IMVT
Track This Portfolio

Track Bridgefront Capital, LLC Portfolio

Follow Bridgefront Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bridgefront Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Bridgefront Capital, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email